Fig 2: The inactivation of ERK1/2 and p38 MAPK signaling pathways’ reverses the EphA3-driven proliferation and migration in melanoma cells. A375 and A875 cells transfected with empty vectors or EphA3 overexpressing vectors (EphA3-OE) were pretreated with D98059 (ERK1/2 inhibitor) or SB203580 (p38 MAPK inhibitor). After 48 h transfection, (a) Western blot analysis of ERK1/2, p-ERK1/2, p38MAPK, and p-p38MAPK expressions in these above transfected cells. (b) Proliferation in these above treated cells was determined by CCK-8 assay. (c) Migration in these above treated cells was assessed by scratch wound assays. P < 0.05, **P < 0.01 vs empty vector; ## P < 0.01 vs EphA-OE; && P < 0.01 vs EphA-OE + PD98059 + SB203580.

Fig 3: MiR-3666 overexpression abrogates the EphA3-driven proliferation and migration in melanoma cells through MAPK/ERK signaling pathway. Empty vectors, EphA3 overexpressing vectors (EphA3-OE), miR-3666 mimic (mimic), mimic NC, and EphA3-OE+ mimic were introduced into A375 and A875 cells. After 48 h transfection, (a) Western blot analysis of EphA3 expression in these above transfected cells. (b) Proliferation in these above transfected cells was determined by CCK-8 assay. (c) Migration in these above transfected cells was assessed by scratch wound assays. (d) Western blot analysis of ERK1/2, p-ERK1/2, p38MAPK, and p-p38MAPK expressions in these above transfected cells. *P < 0.05, **P < 0.01 vs empty vector; # P < 0.05, ## P < 0.01 vs mimic NC; & P < 0.05, && P < 0.01 vs OE + mimic. OE + mimic: EphA3-OE + mimic.